Non-covid mRNA Vaccine and Therapeutics Market Forecasted for USD 1.68 Billion Expansion by 2031 Fueled by R&D Investment and Post-Pandemic Applications

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Non-covid mRNA Vaccine and Therapeutics Market Size, Share & Trends Analysis Report By Product Type (mRNA Therapeutic, mRNA Vaccines), By Therapeutic Area (Infectious Diseases, Oncological Disorders, Other Disorders), By Route of Administration (Intravenous, Intramuscular, Intranasal, Others)- Market Outlook and Industry Analysis 2031"

The Global Non-covid mRNA Vaccine and Therapeutics Market is valued at US$ 370.0 Mn in 2024, and it is expected to reach US$ 1,684.80 Mn by 2031, with a CAGR of 24.20% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2814

Advancements in messenger RNA (mRNA) technology are rapidly transforming the landscape of medical therapeutics and vaccines, setting the stage for significant growth in the non-COVID mRNA therapeutics and vaccine market. This cutting-edge approach employs synthetic mRNA to program cells to synthesize specific proteins, thereby enabling the treatment and prevention of various diseases, including infectious illnesses, cancers, and certain genetic conditions. Unlike conventional vaccines, which introduce attenuated or inactivated pathogens, mRNA vaccines stimulate the body's immune system by instructing cells to produce antigenic proteins internally, offering a more agile and efficient response to evolving health threats. This inherent adaptability underscores mRNA's potential as a highly flexible platform for both prophylactic and therapeutic applications.

The scope of non-COVID mRNA therapeutics continues to expand across multiple disease areas. Numerous vaccine candidates targeting infectious diseases such as influenza, HIV, and Zika virus are currently in development, with the goal of inducing strong and durable immune responses. In oncology, mRNA-based therapies are being engineered to target tumor-specific antigens, supporting the development of personalized cancer vaccines tailored to an individual's unique tumor profile. Additionally, mRNA technology is demonstrating promise in the treatment of genetic disorders by enabling the production of deficient or defective proteins within the body.

The commercial value of mRNA platforms lies in their rapid manufacturing capabilities, scalability, and established safety and efficacy profiles. These attributes position mRNA therapeutics as a pivotal innovation in addressing unmet clinical needs across a broad spectrum of medical conditions, signaling a transformative shift in how future treatments and vaccines will be developed and deployed.

List of Prominent Players in the Non-covid mRNA Vaccine and Therapeutics Market:
• CureVac
• Anima Biotech
• Arcturus Therapeutics
• BioNTech (Pfizer)
• eFFECTOR Therapeutics, Inc.
• eTheRNA
• Ethris (AstraZeneca)
• H3 Biomedicine Inc. (Eisai Inc.)
• In-Cell-Art
• Ionis Pharmaceuticals, Inc.
• Kernal Biologics
• Moderna
• RNAimmune (Sirnaomics)
• Silence Therapeutics
• Skyhawk Therapeutics, Inc.
• Stemirna Therapeutics Co., Ltd.
• Tiba Biotechnology
• Translate Bio Sanofi)
• Ziphius Therapeutics NV

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The non-COVID mRNA vaccine and therapeutics market is experiencing robust growth, driven by ongoing advancements in technology, delivery mechanisms, stability, and clinical efficacy. Innovations such as lipid nanoparticle (LNP) delivery systems have played a pivotal role in enhancing the effectiveness and safety of mRNA-based treatments. The versatility of mRNA platforms enables their application across a wide spectrum of therapeutic areas, including infectious disease prevention, oncology, and the treatment of genetic disorders.

The demonstrated scalability and rapid production capabilities of mRNA-evident during the COVID-19 pandemic-highlight the platform's potential for high-volume manufacturing in response to urgent healthcare needs. In addition, the strong safety profile associated with mRNA vaccines, coupled with increased funding and strategic investments post-pandemic, continues to accelerate market development. Notably, Sanofi's acquisition of Translate Bio has reinforced its mRNA Center of Excellence, enabling further innovation across vaccine development, immunology, oncology, and rare disease treatment.

Challenges:
Despite promising advancements, several obstacles persist in the development and commercialization of non-COVID mRNA therapeutics. Fragmented supply chains and reliance on multiple external vendors often result in operational inefficiencies and delays, particularly for emerging biotechnology firms with limited internal capabilities. Additionally, limited availability of GMP-grade raw materials contributes to production bottlenecks, complicating the manufacturing timeline. The complexity of producing purified, contamination-free mRNA further intensifies these challenges, making the process resource-intensive and technically demanding.

Regional Trends:
North America continues to lead the global non-COVID mRNA therapeutics market, supported by a well-established infrastructure for biomedical research and a strong presence of pharmaceutical and biotechnology companies. The region benefits from close collaboration between academic institutions, research organizations, and private-sector stakeholders, fostering a dynamic environment for innovation and product development. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) provide frameworks that facilitate expedited review and approval of mRNA-based products. A key milestone includes the FDA's approval of Moderna's mRESVIA vaccine, designed to protect individuals aged 60 and older from severe respiratory illness caused by RSV. These factors-combined with robust public and private investment-position North America at the forefront of advancements in mRNA-based therapeutics and vaccines.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2814

Recent Developments:
• In Jan 2023, Moderna, Inc. announced a definitive agreement to acquire OriCiro for $85 million. This acquisition provides Moderna with advanced tools for cell-free synthesis and amplification of plasmid DNA, a crucial component in the mRNA manufacturing process.
• In Aug 2021, Sanofi entered into a definitive agreement to acquire Translate Bio, a clinical-stage mRNA therapeutics company, for $38.00 per share in cash, totaling approximately $3.2 billion. Both companies' Boards of Directors have unanimously approved the transaction, aiming to accelerate Sanofi's development of mRNA-based therapeutics and vaccines.

Segmentation of Non-covid mRNA Vaccine and Therapeutics Market-
Non-covid mRNA Vaccine and Therapeutics Market- By Product Type
• mRNA Therapeutic
• mRNA Vaccines
Non-covid mRNA Vaccine and Therapeutics Market- By Therapeutic Area
• Infectious Diseases
o Influenza
o Respiratory Syncytial Virus (RSV)
o Cytomegalovirus
o Others
• Oncological Disorders
• Other Disorders
Non-covid mRNA Vaccine and Therapeutics Market- By Route of Administration
• Intravenous
• Intramuscular
• Intranasal
• Others
Non-covid mRNA Vaccine and Therapeutics Market- By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/non-covid-mrna-vaccine-and-therapeutics-market/2814

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.